Business Context and Reporting Period
This Form 8-K Current Report from Anavex Life Sciences Corp. (AVXL) covers the period ending September 27, 2021. The filing reports a significant corporate event regarding the listing status of the Company's common stock on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing event and does not contain financial statement data.
Material Changes
- Listing Upgrade: The Company received approval from The Nasdaq Stock Market LLC to list its Common Stock on the Nasdaq Global Select Market, upgrading from the Nasdaq Capital Market.
- Trading Commencement: Trading on the Nasdaq Global Select Market under the ticker symbol "AVXL" commenced on September 27, 2021.
Outlook, Risks, and Management Commentary
Management issued a press release (Exhibit 99.1) announcing the commencement of trading on the upgraded market tier. The filing does not contain specific forward-looking guidance, risk factors, or contingencies beyond the successful execution of the listing upgrade.
Investor Verification Checklist
- Confirm the ticker symbol remains "AVXL" on the Nasdaq Global Select Market.
- Review the attached Press Release (Exhibit 99.1) for additional details on the listing approval.
- Verify the Company's continued compliance with Nasdaq Global Select Market listing standards.